Business

Know the Business

NexgenRx is a tiny Canadian SaaS toll-booth sitting between self-insured employers, union trusts, and pharma programs on one side, and the doctors, dentists, and pharmacies they pay on the other. The economic engine is boringly good — 83% gross margins on recurring per-member and per-claim fees, one operating segment, 1M lives covered and roughly C$1B of claims adjudicated in 2025 against only C$17.9M of its own revenue. The market is probably underestimating that the business finally crossed the profitability inflection (FY2020 → present) and now pays out essentially all of its earnings as dividends at a C$28M market cap, and overestimating that an "independent TPA" can wrest material share from Sun Life, Manulife and Canada Life, who together with Desjardins own 80%+ of the group-benefits market.

1. How This Business Actually Works

NexgenRx is a third-party administrator (TPA) running a claims-adjudication SaaS — think of it as Stripe for Canadian drug/dental/extended-health claims, except the money it handles (C$1B+) dwarfs its own revenue (C$17.9M) by roughly 55×. The revenue is a toll, not a float.

No Results

Mix is estimated — the company reports a single "benefits administration services" segment. Annual release highlights "organic growth of 12% in administration and transaction revenue combined," implying those two streams are the dominant recurring block.

The economic engine in three facts

Gross Margin FY2025

83.3

EBITDA Margin FY2025

17.8

Claims Adjudicated / Revenue

Once the platform is built, the incremental cost of processing one more claim is near zero. Cost of revenue is just 16.7% of sales — mostly pharmacy network fees and payment rails, not labour. That is why the gross-profit line has outrun revenue since FY2019 (gross profit went from C$8.4M to C$14.9M, a 78% lift on 88% revenue growth) and why operating leverage shows up the moment revenue crosses the fixed-cost threshold.

Bottleneck and bargaining power

The bottleneck isn't technology. It's client acquisition in a concentrated market — the buyers are insurers, multi-employer union trusts, pharma patient-support programs and large self-insured employers, and the sales cycle is long. Once a plan is live on NexSys/NexAdmin, the switching cost is high (regulated data migration, member re-enrolment, provider network re-contracting), which is why churn appears negligible — the CEO talks about "organic growth of existing clients" quarter after quarter, and management hasn't had to disclose any material client loss since FY2019.

Bargaining power sits more with the plan sponsor than with NexgenRx. Big insurers operate their own TPAs in-house; independent buyers (union trusts, pharma PSPs, mid-market employers) shop NexgenRx precisely to avoid the incumbents, which caps pricing but also caps competition because the incumbents don't want this work at this size.

2. The Playing Field

NexgenRx is a sub-scale independent inside a market owned by the big Canadian life-and-health insurers. The named peers below all dwarf it — the right way to read this table is "which economics would I rather own" rather than "who wins head-to-head."

No Results

NXG is roughly **one one-thousandth** the size of SLF or GWO by market cap, and the insurers carry TPA arms inside insurance franchises that span individual life, wealth, and asset management. TELUS is the most relevant direct competitor because TELUS Health (post-LifeWorks) sells benefits administration as a standalone SaaS — but at TELUS, the whole health segment is a rounding error on a C$20B telco.

Positioning: scale vs. focus

NexgenRx sits in the lower-left: tiny but with a margin profile inside the range of peers many thousand times its size. TELUS' 33% EBITDA margin is a telco, not a TPA benchmark — the comparable pure-benefits margin would be closer to SLF/GWO/MFC's 13–15%. On that reading, NexgenRx already earns above-peer EBITDA margins at 1/2000th the scale, which tells you the SaaS model has genuine unit economics.

3. Is This Business Cyclical?

Not really — the revenue is recurring PEPM fees on benefit plans that employers and unions must sustain regardless of the macro cycle. What is cyclical is small-cap capital availability, and that is the real risk.

Look at the revenue history through three recessions (2008 GFC, 2015–16 oil shock, 2020 COVID):

Revenue rose in every single one of those years — including +16% in GFC-year 2008, +23% in oil-shock 2015 on a restated base, and +16% in COVID-2020. Claims utilization is driven by demographics (aging membership), not GDP.

The cyclical exposure is elsewhere:

Dental/optical claim frequency dips in recessions as members defer discretionary care. This lowers transaction-fee revenue at the margin but barely shows up in the annual numbers because PEPM admin fees are the bigger block.
Capital markets. NexgenRx raised equity in its loss-making years (share count rose from 10M in 2005 to 77M today). If it ever needs to raise again during a small-cap drought, dilution would hurt. The mitigation is that the business is now self-funding: FY2025 EBITDA C$3.4M against ~zero net debt.
Large-client concentration. One lost major client would dent transaction revenue for 6–12 months until replaced. The FY2025 Q2 release calls out "a new major client" as a milestone — which, at this size, means individual wins and losses are visible in the quarterly numbers.

4. The Metrics That Actually Matter

Forget the income statement. For a micro-cap SaaS TPA, five metrics tell you whether the thesis is working.

No Results

The two I would fixate on are organic revenue growth and dividend coverage. Growth above 10% means the independent-TPA value proposition is still pulling share. Coverage trending above 1.5x would signal the business is building cash; staying at 1.0x signals the CEO is using the dividend to compensate long-time shareholders for the years of dilution — honourable, but it caps re-investment.

The FY2022–FY2023 dip is the key footnote: after turning profitable in 2019, EBITDA wobbled while the company built out NexAdmin and patient-support capabilities. FY2024 and FY2025 restored the trajectory. If FY2026 prints another 15%+ EBITDA margin, the inflection is durable; if it rolls over again, the business is still fighting fixed-cost pressure.

5. What I'd Tell a Young Analyst

This is a successful small business masquerading as a public stock. Before building a valuation, go back and read the FY2005 income statement — C$27,000 of revenue on a C$6.2M loss — and then read FY2025 — C$17.9M revenue on C$1.3M net income. That 20-year arc is what you're really paying for: a founder-operator who built a niche SaaS to profitable scale, survived dilution (share count went from 10M to 77M), and now uses cash flow to pay investors back via a dividend that soaks up ~100% of earnings.

Three things to watch that change the thesis:

**Bullish signal:** Dividend coverage expands above 1.5x AND EBITDA margin holds above 18%. That combination would mean management is retaining cash for real re-investment (product, bolt-on M&A), not just returning it. At this market cap, any incremental reinvested C$1M compounds visibly.

**Bearish signal:** Organic admin + transaction growth falls below 7% for two straight years. That would say the independent-TPA pitch is losing to Sun Life / Manulife / TELUS Health at the mid-market level, and the only remaining lever is price cuts, which would destroy the margin story.

**The thing the market is probably missing:** this is not a traditional lossmaking TSXV micro-cap — it is already cash-flow positive, debt-free, growing 9–12% on recurring revenue, and throwing off enough cash to pay a dividend. The relevant comp set is not junior exploration or biotech; it is **small-cap vertical SaaS**, where 2× sales and 8–10× EBITDA would be a kind starting point. On FY2025 numbers, NXG trades at **~1.5× sales and ~7× EV/EBITDA.** That's cheap if execution holds — but it is cheap for a reason: liquidity is near-zero, the CEO is 20+ years in and without a disclosed succession plan, and a single lost major client is a real number at this scale.

What would change my mind: (a) a disclosed new pharma PSP or union-trust mandate worth more than C$2M of annual revenue — a single contract can move the top line by ~10%; (b) an acquisition of a competing independent TPA (ClaimSecure, Benecaid) that consolidates the non-insurer corner of the market; (c) a buyout by a larger benefits tech consolidator — at C$28M market cap and a dominant independent niche, this is a strategic tuck-in for someone, not a standalone compounder.

Don't confuse the small size for low quality. Confuse it for low liquidity.